-- Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of
approximately $0.4 million, within the Company's guidance range of
negative $1 million to positive $2 million.
-- Adjusted EBITDA improved approximately $3.1 million sequentially from an
adjusted EBITDA loss of $3.5 million in the second quarter of 2026,
driven primarily by a 34% sequential reduction in selling and marketing
expenses and reduction of overall non-clinical expenses.
-- GAAP net loss from continuing operations attributable to common
stockholders of $5.2 million, or $0.11 per share, compared with $8.4
million, or $0.18 per share, in the second quarter of 2026.
-- Total active subscribers increased 13% year-over-year to approximately
350,000.
-- LifeMD Pharmacy shipment volume grew 58.3% year-over-year.
-- Exited the quarter with $21.9 million of cash and no debt; subsequent to
quarter-end, closed on a $12.5 million senior secured term loan to
replace the Company's previous credit facility.
-- Entered into arrangements with both Novo Nordisk and Eli Lilly, enabling
LifeMD's pharmacy to begin dispensing self-pay branded GLP-1 medications,
including Wegovy, Wegovy Pill, Ozempic, Zepbound, and Foundayo, to
patients nationwide.
-- Entered into an exclusive relationship with AT&T to provide its 100
million wireless and fiber customers and 110,000 U.S. employees access to
LifeMD's healthcare and pharmacy services.
-- Expecting fourth quarter 2026 revenue of between $46 million and $49
million, and Adjusted EBITDA of between negative $4 million to negative
$2 million.
Conference call begins at 4:30 p.m. Eastern time today
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today reported financial results for the third quarter ended September 30, 2026.
Management Commentary
"We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing," said Justin Schreiber, Chairman and CEO of LifeMD. "We're helping more people access high-quality healthcare, and we're getting more efficient at doing it. From May to September, cost per acquisition fell 32% while monthly media spend declined 45%. Adjusted EBITDA improved approximately $3.1 million sequentially to roughly breakeven, and we expect to sustain or improve these unit economics going forward.
"Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year. We deliberately reduced marketing spend and prioritized longer patient commitments, and our partnerships took longer to ramp than we expected. Those factors weighed on revenue this quarter, but we believe our decisions put us in a stronger position to grow profitably.
"Our pharmacy has begun dispensing branded GLP-1 medications from Eli Lilly and Novo Nordisk. Our exclusive relationship with AT&T gives its 100 million wireless and fiber customers and 110,000 U.S. employees access to our healthcare and pharmacy services. We also made significant progress on our enterprise healthcare offering, which we will begin marketing to businesses across the country in the fourth quarter. Our women's health program continued to improve, and we added experienced leadership to accelerate its growth. Our focus now is turning this work into revenue growth while maintaining the operating discipline we established this quarter."
"Gross margin was approximately 82% in the quarter, compared with approximately 89% in the second quarter and 85% a year ago. The decline primarily reflects a change in presentation, not economics: under our new branded fulfillment arrangements, medications fulfilled by our own pharmacy are recognized on a gross revenue basis," said Atul Kavthekar, Chief Financial Officer of LifeMD. "We reduced selling and marketing expense by $9.5 million sequentially to $18.5 million. General and administrative expense increased slightly from the second quarter to $14.7 million, reflecting clinical capacity added to support our new partnerships, partially offset by efficiencies in non-clinical functions. We ended the quarter with $21.9 million of cash and no debt. Subsequent to quarter end, we closed a $12.5 million non-convertible senior secured term loan with Avenue Capital. It replaces our prior revolving credit facility and gives us significantly greater flexibility to fund the working capital our branded fulfillment arrangements may require."
Third Quarter 2026 Financial Highlights
All comparisons are with the third quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.
-- Total revenue was $44.6 million, compared with $47.7 million in the
prior-year period, a decrease of approximately 7%.
-- Gross profit was $36.4 million, compared with $40.7 million in the
prior-year period. Gross margin was approximately 82%, compared with
approximately 85% in the prior-year period, a decline of approximately
370 basis points, primarily reflecting the gross revenue presentation of
branded medications fulfilled by our pharmacy.
-- Selling and marketing expenses decreased 18% year-over-year, and 34%
sequentially, to $18.5 million.
-- General and administrative expenses increased 6% year-over-year to $14.7
million, reflecting added clinical capacity.
-- GAAP net loss from continuing operations attributable to common
stockholders was $5.2 million, or $0.11 per share, compared with a GAAP
net loss from continuing operations attributable to common stockholders
of $5.4 million, or $0.12 per share, in the prior-year period.
-- Adjusted EBITDA was a loss of approximately $0.4 million, compared with
adjusted EBITDA of approximately $2.8 million in the prior-year period.
-- Cash totaled $21.9 million as of September 30, 2026, and the Company had
no debt at quarter end.
-- The number of active subscribers increased 13% year-over-year to
approximately 350,000 at quarter end.
($ in 000s) Three Months Ended September 30, Y-o-Y
---------------------------------------- --------
Key Performance
Metrics 2026 2025 % Growth
------------------ ---------------- ---------------- --------
Revenue $ 44,625 $ 47,728 -7%
Gross Profit $ 36,376 $ 40,666 -11%
Gross Margin % 82% 85% -370bpts
Adjusted EBITDA $ (413) $ 2,787 -115%
Active Subscribers 349,744 310,818 13%
Financial Guidance
For the fourth quarter of 2026, the Company expects:
-- Revenue in the range of $46 million to $49 million.
-- Adjusted EBITDA in the range of negative $4 million to negative $2
million.
For the full year 2026, the Company expects (revised from previous guidance):
-- Revenue in the range of $188 million to $191 million, compared with
previous guidance of $205.5 million to $212.5 million.
-- Adjusted EBITDA in the range of negative $12.6 million to negative $10.6
million, compared with previous guidance of negative $6.0 million to
breakeven.
Conference Call
LifeMD's management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company's financial results and outlook, and answer questions. Details for the call are as follows:
Toll-free dial-in number: (877) 270-2148 International dial-in number: +1 (412) 902-6510 Conference ID: LifeMD, Inc. Third Quarter 2026 Results
A live and archived webcast will be available in the Investors section of the Company's website at ir.lifemd.com.
About LifeMD, Inc.
LifeMD(R) is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe," "expect," "anticipate, " "project," "should," "plan," "will," "may," "intend," "estimate," "predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded
products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
ir@lifemd.com
Media Contact
press@lifemd.com
Tables to Follow
LIFEMD, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, 2026 December 31, 2025
-------------------- -------------------
ASSETS
Current Assets
Cash $ 21,921,769 $ 36,786,318
Receivables, net 13,249,849 2,485,882
Product deposit 218,690 320,217
Inventory, net 10,348,601 2,773,576
Other current assets 3,522,349 2,646,077
Total Current Assets 49,261,258 45,012,070
Non-current Assets
Equipment, net 1,905,154 2,444,717
Right of use assets, net 4,622,463 5,267,857
Capitalized software, net 10,329,573 10,604,946
Intangible assets, net 166,583 262,334
Total Non-current
Assets 17,023,773 18,579,854
Total Assets $ 66,285,031 $ 63,591,924
================ ===============
LIABILITIES AND
STOCKHOLDERS' (DEFICIT)
EQUITY
Current Liabilities
Accounts payable $ 37,736,899 $ 14,149,154
Accrued expenses 12,842,607 14,214,393
Current operating lease
liabilities 691,719 642,422
Deferred revenue 10,433,507 10,573,442
---------------- ---------------
Total Current
Liabilities 61,704,732 39,579,411
Long-term Liabilities
Non-current operating
lease liabilities 5,159,954 5,681,374
Total Liabilities 66,864,686 45,260,785
Commitments and
Contingencies
Stockholders' (Deficit)
Equity
Series A Preferred Stock,
$0.0001 par value;
1,610,000 shares
authorized, 1,400,000
shares issued and
outstanding as of
September 30, 2026 and
December 31, 2025 140 140
Common Stock, $0.01 par
value; 100,000,000
shares authorized,
48,358,877 and
46,760,016 shares
issued, 48,255,837 and
46,656,976 outstanding
as of September 30, 2026
and December 31, 2025,
respectively 483,589 467,600
Additional paid-in
capital 255,443,609 251,455,616
Accumulated deficit (256,343,292) (233,428,516)
Treasury stock, 103,040
shares, at cost, as of
September 30, 2026 and
December 31, 2025 (163,701) (163,701)
---------------- ---------------
Total LifeMD, Inc.
Stockholders'
(Deficit) Equity (579,655) 18,331,139
Total Liabilities and
Stockholders'
(Deficit) Equity $ 66,285,031 $ 63,591,924
================ ===============
LIFEMD, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Nine Months Ended September
September 30, 30,
-------------------------- ------------------------------
2026 2025 2026 2025
----------- ----------- ------------ ------------
Telehealth
revenue, net $44,625,086 $47,727,942 $142,048,848 $146,861,697
Cost of
telehealth
revenue 8,249,469 7,061,651 19,605,877 21,627,901
Gross profit 36,375,617 40,666,291 122,442,971 125,233,796
---------- ---------- ----------- -----------
Expenses
Selling and
marketing
expenses 18,500,609 22,563,994 76,411,416 66,988,030
General and
administrative
expenses 14,654,524 13,800,377 43,468,661 42,995,255
Other operating
expenses 3,453,051 2,800,013 9,673,184 8,072,564
Customer
service
expenses 2,351,426 2,784,320 8,103,717 9,086,549
Development
costs 1,882,508 1,844,269 5,470,005 5,526,379
Total
expenses 40,842,118 43,792,973 143,126,983 132,668,777
---------- ---------- ----------- -----------
Operating loss
from
continuing
operations (4,466,501) (3,126,682) (20,684,012) (7,434,981)
Interest
(expense)
income, net (3,212) (260,621) 98,924 (1,385,046)
Loss on debt
extinguishment - (1,155,851) - (1,155,851)
Loss from
continuing
operations
before income
taxes (4,469,713) (4,543,154) (20,585,088) (9,975,878)
Income tax
provision - (31,823) - (31,823)
---------- ---------- ----------- -----------
Net loss from
continuing
operations (4,469,713) (4,574,977) (20,585,088) (10,007,701)
Net income from
discontinued
operations - 935,013 - 4,821,519
Net loss (4,469,713) (3,639,964) (20,585,088) (5,186,182)
Net income
attributable
to
noncontrolling
interests of
discontinued
operations - 249,462 - 1,286,382
---------- ---------- ----------- -----------
Net loss
attributable
to LifeMD,
Inc. (4,469,713) (3,889,426) (20,585,088) (6,472,564)
Preferred stock
dividends (776,563) (776,563) (2,329,688) (2,329,688)
Net loss
attributable
to LifeMD,
Inc. common
stockholders $(5,246,276) $(4,665,989) $(22,914,776) $ (8,802,252)
========== ========== =========== ===========
Basic (loss)
earnings per
share
attributable to
LifeMD, Inc.
common
stockholders
Continuing
operations $ (0.11) $ (0.12) $ (0.48) $ (0.28)
Discontinued
operations - 0.01 - 0.08
Basic loss
per share $ (0.11) $ (0.10) $ (0.48) $ (0.20)
========== ========== =========== ===========
Diluted (loss)
earnings per
share
attributable to
LifeMD, Inc.
common
stockholders
Continuing
operations $ (0.11) $ (0.12) $ (0.48) $ (0.28)
Discontinued
operations - 0.01 - 0.08
Diluted loss
per share $ (0.11) $ (0.10) $ (0.48) $ (0.20)
========== ========== =========== ===========
Weighted
average number
of common
shares
outstanding:
Basic 48,182,152 46,162,625 47,772,180 44,575,553
========== ========== =========== ===========
Diluted 48,182,152 46,162,625 47,772,180 44,575,553
========== ========== =========== ===========
LIFEMD, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended Nine Months Ended September
September 30, 30,
--------------------------- ------------------------------
2026 2025 2026 2025
----------- ------------ ------------ ------------
CASH FLOWS FROM
OPERATING
ACTIVITIES
Net loss $(4,469,713) $ (3,639,964) $(20,585,088) $ (5,186,182)
Less: Net income
from
discontinued
operations - 935,013 - 4,821,519
---------- ----------- ----------- -----------
Net loss from
continuing
operations (4,469,713) (4,574,977) (20,585,088) (10,007,701)
Adjustments to
reconcile net
loss from
continuing
operations to net
cash (used in)
provided by
operating
activities:
Amortization of
debt discount - 33,481 - 234,369
Amortization of
capitalized
software 1,727,834 1,597,030 5,116,366 4,712,732
Amortization of
intangibles 31,917 31,917 95,751 62,084
Loss on debt
extinguishment - 1,155,851 - 1,155,851
Depreciation of
fixed assets 301,049 253,031 883,294 583,915
Noncash
operating
lease expense 217,495 217,495 645,394 743,207
Stock
compensation
expense 1,684,445 3,198,036 3,923,462 7,841,178
Changes in Assets
and Liabilities
Receivables (9,507,862) (10,338) (10,763,967) 2,618,396
Product deposit 25,069 (119,518) 101,527 (329,755)
Inventory (7,392,457) (181,027) (7,575,025) (635,024)
Other current
assets (1,035,546) (1,382,528) (876,272) (558,239)
Operating lease
liabilities (165,451) (23,535) (472,123) (171,841)
Deferred
revenue (357,714) (2,322,589) (139,935) (4,864,738)
Accounts
payable 19,579,987 (4,591,851) 23,587,745 3,896,078
Accrued
expenses (1,588,687) 4,529,660 (1,371,786) (1,109,939)
Net cash
(used in)
provided by
operating
activities
of
continuing
operations (949,634) (2,189,862) (7,430,657) 4,170,573
Net cash
provided by
operating
activities
of
discontinued
operations - 2,042,726 - 7,390,125
Net cash
(used in)
provided by
operating
activities (949,634) (147,136) (7,430,657) 11,560,698
========== =========== =========== ===========
CASH FLOWS FROM
INVESTING
ACTIVITIES
Cash paid for
capitalized
software costs (1,322,921) (1,937,544) (4,840,993) (5,884,672)
Purchase of
equipment (170,728) (785,748) (343,731) (1,679,963)
Net cash used
in investing
activities
of
continuing
operations (1,493,649) (2,723,292) (5,184,724) (7,564,635)
Net cash used
in investing
activities
of
discontinued
operations - (871,188) - (2,596,766)
-----------
Net cash used
in investing
activities (1,493,649) (3,594,480) (5,184,724) (10,161,401)
========== =========== =========== ===========
CASH FLOWS FROM
FINANCING
ACTIVITIES
Repayment of debt
instruments - (16,667,433) - (18,719,721)
Sale of common
stock under ATM,
net - 8,721,717 - 8,721,717
Preferred stock
dividends (776,563) (776,563) (2,329,688) (2,329,688)
Cash proceeds
from exercise of
warrants - 464,950 - 464,950
Cash proceeds
from exercise of
options - 5,950 80,520 5,950
Net cash used
in financing
activities
of
continuing
operations (776,563) (8,251,379) (2,249,168) (11,856,792)
Net cash used
in financing
activities
of
discontinued
operations - (449,539) - (761,658)
Net cash used
in financing
activities (776,563) (8,700,918) (2,249,168) (12,618,450)
========== =========== =========== ===========
Net decrease in
cash (3,219,846) (12,442,534) (14,864,549) (11,219,153)
Cash at beginning
of period 25,141,615 36,228,305 36,786,318 35,004,924
Cash at end of
period 21,921,769 23,785,771 21,921,769 23,785,771
Less: Cash of
discontinued
operations at
end of period - 2,838,484 - 2,838,484
Cash of
continuing
operations at
end of period $21,921,769 $ 20,947,287 $ 21,921,769 $ 20,947,287
========== =========== =========== ===========
Cash paid for
interest and
taxes
-----------------
Cash paid during
the period for
interest $ - $ 241,464 $ - $ 1,461,032
========== =========== =========== ===========
Cash paid during
the period for
taxes $ - $ 14,617 $ 361,230 $ 482,471
========== =========== =========== ===========
Non-cash
investing and
financing
activities
-----------------
Cashless exercise
of options $ - $ 253 $ - $ 1,315
========== =========== =========== ===========
Cashless exercise
of warrants $ 3,204 $ - $ 3,204 $ 3,901
========== =========== =========== ===========
Stock issued for
debt conversion $ - $ - $ - $ 1,000,000
========== =========== =========== ===========
Stock issued for
asset
acquisition $ - $ - $ - $ 303,000
========== =========== =========== ===========
About the Use of Non-GAAP Financial Measures
To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor's understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.
Adjusted EBITDA is defined as net loss attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, extraordinary litigation costs, severance and restructuring costs, acquisition expenses, insurance acceptance readiness expenses, preferred stock dividends, stock-based compensation expense, net income from discontinued operations and net income attributable to noncontrolling interests of discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.
We believe the above financial measure is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.
Reconciliation of Net Loss Attributable to LifeMD,
Inc. Common Stockholders to Adjusted EBITDA
(in whole numbers,
unaudited)
Three Months Ended Nine Months Ended September
September 30, 30,
-------------------------- -----------------------------
2026 2025 2026 2025
----------- ----------- ------------ -----------
Net loss
attributable to
LifeMD, Inc.
common
stockholders $(5,246,276) $(4,665,989) $(22,914,776) $(8,802,252)
Interest (income)
expense, net 3,212 227,140 (98,924) 1,150,677
Depreciation and
amortization
expense 2,060,800 1,881,978 6,095,411 5,358,731
Amortization of
debt discount - 33,481 - 234,369
Loss on debt
extinguishment - 1,155,851 - 1,155,851
Financing
transactions
expense - 97,699 - 97,699
Litigation costs
(a) 64,328 959,803 1,112,269 1,699,462
Severance and
restructuring
costs 243,885 - 992,879 102,417
Acquisitions
expenses - (231,571) - 1,783,206
Insurance
acceptance
readiness - 8,190 - 183,330
Taxes - 31,823 - 31,823
Preferred stock
dividends 776,563 776,563 2,329,688 2,329,688
Stock compensation
expense 1,684,445 3,198,036 3,923,462 7,841,178
Net income from
discontinued
operations - (935,013) - (4,821,519)
Net income
attributable to
noncontrolling
interests of
discontinued
operations - 249,462 - 1,286,382
Adjusted EBITDA $ (413,043) $ 2,787,452 $ (8,559,991) $ 9,631,041
========== ========== =========== ==========
(a) For the three and nine months ended September
30, 2026 and 2025, the Company included costs related
to: (1) a class action complaint captioned Johnston
v. LifeMD, Inc., et al., against the Company and certain
executive officers alleging: (i) violations of Section
10(b) of the Securities Exchange Act of 1934, as amended,
and Rule 10b-5 promulgated thereunder by all defendants
for making false and misleading statements; and (ii)
violations of Section 20(a) of the Securities Exchange
Act of 1934, as amended, by the individual officer
defendants for violating their duty to disseminate
accurate and truthful information, and (2) a heavily
negotiated executive separation agreement. For the
three and nine months ended September 30, 2025, the
Company also included costs related to a class action
complaint alleging, inter alia, unauthorized disclosure
of certain information of class members to third parties
(the Marden v. LifeMD, Inc. case).
Comments